| D007192 |
Indenes |
A family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins. |
|
|
| D009812 |
Odorants |
The volatile portions of chemical substances perceptible by the sense of smell. |
Odors,Aroma,Fragrance,Scents,Aromas,Fragrances,Odor,Odorant,Scent |
|
| D010476 |
Perfume |
A substance, extract, or preparation for diffusing or imparting an agreeable or attractive smell, especially a fluid containing fragrant natural oils extracted from flowers, woods, etc., or similar synthetic oils. (Random House Unabridged Dictionary, 2d ed) |
|
|
| D003257 |
Consumer Product Safety |
The sum total of measures taken and regulatory policies enacted to ensure the safe use of consumer products. |
Safety, Consumer Product,Product Approval,Product Approvals,Product Safety, Consumer |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000818 |
Animals |
Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. |
Animal,Metazoa,Animalia |
|
| D012486 |
Salmonella typhimurium |
A serotype of Salmonella enterica that is a frequent agent of Salmonella gastroenteritis in humans. It also causes PARATYPHOID FEVER. |
Salmonella typhimurium LT2 |
|
| D018570 |
Risk Assessment |
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) |
Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments |
|
| D019055 |
No-Observed-Adverse-Effect Level |
The highest dosage administered that does not produce toxic effects. |
NOAEL,No-Observed-Effect Level,Acceptable Daily Intake,Tolerable Daily Intake,Acceptable Daily Intakes,Daily Intake, Acceptable,Daily Intake, Tolerable,Daily Intakes, Acceptable,Daily Intakes, Tolerable,Intake, Acceptable Daily,Intake, Tolerable Daily,Intakes, Acceptable Daily,Intakes, Tolerable Daily,Level, No-Observed-Adverse-Effect,Level, No-Observed-Effect,Levels, No-Observed-Adverse-Effect,Levels, No-Observed-Effect,No Observed Adverse Effect Level,No Observed Effect Level,No-Observed-Adverse-Effect Levels,No-Observed-Effect Levels,Tolerable Daily Intakes |
|
| D023381 |
Endpoint Determination |
Establishment of the level of a quantifiable effect indicative of a biologic process. The evaluation is frequently to detect the degree of toxic or therapeutic effect. |
Endpoint Assay,End Point Assay,End Point Determination,Assay, End Point,Assay, Endpoint,Assays, End Point,Assays, Endpoint,Determination, Endpoint,Determinations, End Point,Determinations, Endpoint,End Point Assays,End Point Determinations,Endpoint Assays,Endpoint Determinations,Point Assay, End,Point Assays, End,Point Determinations, End |
|